Insight Molecular Diagnostics (IMDX) Aktievy
Insight Molecular Diagnostics Inc. är verksamt som ett företag inom precisionsdiagnostik i USA och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 0/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 3/6 |
| Utdelningar | 0/6 |
IMDX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Insight Molecular Diagnostics Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$5.08 |
| 52 veckors högsta | US$8.51 |
| 52 veckors lägsta | US$2.33 |
| Beta | 1.76 |
| 1 månads förändring | -11.81% |
| 3 månaders förändring | 60.25% |
| 1 års förändring | 77.62% |
| 3 års förändring | 16.89% |
| 5 års förändring | -95.21% |
| Förändring sedan börsintroduktionen | -95.94% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jul 08
IMDX: Clinical Data And Registry Validation Will Support Higher Future Returns
Analysts have raised their fair value estimate for Insight Molecular Diagnostics from $9.00 to $12.00, citing updated assumptions around revenue growth, profit margins, and a lower projected future P/E multiple. What’s in the News for Insight Molecular Diagnostics Insight Molecular Diagnostics reported an online publication in Clinical Chemistry highlighting high concordance between its digital PCR based GraftAssure transplant monitoring test and a next generation sequencing assay for donor derived cell free DNA in kidney transplant patients, with agreement of 99.2% at the 0.5% dd cfDNA threshold.
Uppdatering av berättelse • Jun 24
IMDX: FDA Review And New Transplant Data Will Drive Bullish Repricing
Analysts have adjusted their price target for Insight Molecular Diagnostics to $8.33. This reflects updated assumptions on the discount rate, profit margin, and future P/E, while keeping the fair value estimate unchanged at $8.33.Uppdatering av berättelse • Jun 06
IMDX: FDA Review Of Transplant Rejection Test Will Drive Bullish Repricing
Analysts have adjusted their price target for Insight Molecular Diagnostics from $10.50 to about $8.33, reflecting updated assumptions around revenue growth, profit margins, and future P/E expectations. What's in the News Insight Molecular Diagnostics submitted its GraftAssureDx donor derived cell free DNA (dd cfDNA) assay kit to the FDA for regulatory review, following 12 years of clinical development and three years of focused product work.Recent updates
Uppdatering av berättelse • Jul 08
IMDX: Clinical Data And Registry Validation Will Support Higher Future Returns
Analysts have raised their fair value estimate for Insight Molecular Diagnostics from $9.00 to $12.00, citing updated assumptions around revenue growth, profit margins, and a lower projected future P/E multiple. What’s in the News for Insight Molecular Diagnostics Insight Molecular Diagnostics reported an online publication in Clinical Chemistry highlighting high concordance between its digital PCR based GraftAssure transplant monitoring test and a next generation sequencing assay for donor derived cell free DNA in kidney transplant patients, with agreement of 99.2% at the 0.5% dd cfDNA threshold.Uppdatering av berättelse • Jun 24
IMDX: FDA Review And New Transplant Data Will Drive Bullish Repricing
Analysts have adjusted their price target for Insight Molecular Diagnostics to $8.33. This reflects updated assumptions on the discount rate, profit margin, and future P/E, while keeping the fair value estimate unchanged at $8.33.Uppdatering av berättelse • Jun 06
IMDX: FDA Review Of Transplant Rejection Test Will Drive Bullish Repricing
Analysts have adjusted their price target for Insight Molecular Diagnostics from $10.50 to about $8.33, reflecting updated assumptions around revenue growth, profit margins, and future P/E expectations. What's in the News Insight Molecular Diagnostics submitted its GraftAssureDx donor derived cell free DNA (dd cfDNA) assay kit to the FDA for regulatory review, following 12 years of clinical development and three years of focused product work.Analysartikel • May 15
We're Keeping An Eye On Insight Molecular Diagnostics' (NASDAQ:IMDX) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Uppdatering av berättelse • May 15
IMDX: FDA Submission And Strengthened Cash Position Will Drive Bullish Repricing
Insight Molecular Diagnostics' analyst price target has moved from $8 to $12, with analysts pointing to secured funding from the recent $26M offering and the anticipated FDA submission for GraftAssureDx as key factors supporting this revision. Analyst Commentary Bullish Takeaways Bullish analysts view the move to a US$12 price target as reflecting reduced funding risk after the recent US$26M offering, which they see as supportive for execution on pending milestones.Uppdatering av berättelse • Apr 28
IMDX: Upcoming FDA Review And Cash Cushion May Support Bullish Repricing
Analysts have lifted their price target on Insight Molecular Diagnostics to $12 from $8, citing the recently completed $26M offering, which secures cash beyond a potential GraftAssureDx approval and an expected FDA submission in the coming weeks, as key drivers of their updated view. Analyst Commentary Bullish Takeaways Bullish analysts view the new $12 price target as reflecting improved funding visibility, with the recent $26M offering seen as supportive of ongoing operations past a potential GraftAssureDx approval.Uppdatering av berättelse • Apr 13
IMDX: Upcoming FDA Submission And Cash Runway May Support Bullish Repricing
Analysts have raised their price target on Insight Molecular Diagnostics to $12 from $8, citing the recent $26M capital raise and expectations around an upcoming FDA submission for GraftAssureDx as key supports for the new outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a US$12 price target as reflecting higher confidence that the recent US$26M capital raise supports the company through key regulatory milestones.Uppdatering av berättelse • Mar 29
IMDX: Upcoming FDA Review And Capital Raise Will Support Bullish Repricing
Analysts have raised their price target on Insight Molecular Diagnostics to $12 from $8, citing the recent $26,000,000 capital raise and the expected FDA submission for GraftAssureDx in the coming weeks as key factors supporting the revised target. Analyst Commentary Recent research updates give you a clearer picture of how the Street is reacting to Insight Molecular Diagnostics after its latest funding and upcoming regulatory milestones.Uppdatering av berättelse • Mar 12
IMDX: Upcoming FDA Submission And Capital Raise Will Drive Bullish Repricing
Analysts have lifted their price target on Insight Molecular Diagnostics to $12 from $8, citing the recent $26m capital raise and expectations for an upcoming FDA submission for GraftAssureDx as key supports for the updated view. Analyst Commentary Bullish Takeaways Bullish analysts point to the move in the price target to $12 as reflecting higher confidence that the recent $26m capital raise supports the company through key regulatory milestones.Uppdatering av berättelse • Feb 26
IMDX: Funding And Upcoming FDA Submission Will Shape Potential Upside
Analysts have lifted their price target on Insight Molecular Diagnostics to $12 from $8, citing secured funding from the recent $26M offering and the anticipated FDA submission for GraftAssureDx as key supports for their updated view. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a $12 price target as reflecting higher conviction that the current funding and product plan can support the company through key milestones.Uppdatering av berättelse • Feb 11
IMDX: Stable Outlook As Regulatory And Transplant Center Expansion Will Shape Upside
Analysts have adjusted their price target on Insight Molecular Diagnostics to reflect an updated fair value of $7.00 per share, a higher assumed future P/E of 121.71, and revised views on the discount rate and profit margin potential. What's in the News Year-end business update outlined commercial progress and the clinical trial status of the GraftAssureDx test kit, including preparation for an in vitro diagnostic de novo submission to the US Food & Drug Administration (FDA).Uppdatering av berättelse • Jan 27
IMDX: Stable Outlook As Regulatory Progress And Transplant Testing Portfolio Will Shape Upside
Analysts have nudged their price target on Insight Molecular Diagnostics higher to reflect slightly refined assumptions on discount rate, profit margin and forward P/E. The updated target is now framed around a fair value of 7.0. What's in the News Year end business update outlines commercial progress for the GraftAssureDx test kit, including clinical trial status and plans for an in vitro diagnostic de novo submission to the United States Food & Drug Administration, alongside additional regulatory submissions and registry study work expected in 2026 (company update).Uppdatering av berättelse • Jan 12
IMDX: Stable Outlook As Transplant Monitoring Pipeline And Regulatory Progress Will Support Upside
Narrative Update on Insight Molecular Diagnostics Analysts have slightly adjusted their price target on Insight Molecular Diagnostics, with the change reflecting updated fair value modeling around a 7.0% discount rate, approximately 41% revenue growth assumptions, a 16.24% profit margin, and a forward P/E near 120x. What's in the News Year end business update provided on commercial progress, including the GraftAssureDx test kit clinical trial and plans for an in vitro diagnostic de novo submission to the US Food & Drug Administration, alongside additional regulatory submissions and registry study work expected in 2026.Uppdatering av berättelse • Dec 25
IMDX: Transplant Monitoring Expansion Will Drive Future Market Leadership
Analysts have modestly raised their price target on Insight Molecular Diagnostics to reflect incremental improvements in long term profit margin assumptions and a slightly lower discount rate, while maintaining broadly consistent growth expectations and valuation multiples. What's in the News Publication of a case study in the American Journal of Transplantation highlighted Insight Molecular Diagnostics' GraftAssure assay as essential for monitoring a high risk kidney transplant patient undergoing novel CD19 CAR T therapy without traditional immunosuppression (Key Developments).Uppdatering av berättelse • Dec 11
IMDX: Transplant Monitoring Advances Will Drive Future Market Momentum
Narrative Update on Insight Molecular Diagnostics The analyst price target for Insight Molecular Diagnostics has been modestly revised upward by analysts, reflecting slightly higher fair value estimates supported by incremental improvements in projected discount rate, revenue growth, profit margin, and future price to earnings assumptions. What's in the News A published clinical study in the American Journal of Transplantation highlighted the GraftAssure assay as critical for long-term monitoring of a high-risk kidney transplant patient treated with novel CD19 CAR T therapy, confirming absence of rejection during cancer treatment (American Journal of Transplantation).Uppdatering av berättelse • Nov 27
IMDX: Expanding Clinical Trial Participation Will Drive Market Momentum
Analysts have raised their price target for Insight Molecular Diagnostics from $6.13 to $7.00 per share, citing stronger expected revenue growth and improving profit margins in their updated forecasts. What's in the News Insight Molecular Diagnostics published results showing their GraftAssure assay enabled long-term non-immunosuppressed kidney transplant survival with no rejection, following CD19 CAR-T therapy in a complex patient case (study published in the American Journal of Transplantation).Seeking Alpha • Nov 14
Insight Molecular Diagnostics: GraftAssureDX FDA Submission Warrants Hold Rating
Summary Initiating coverage of Insight Molecular Diagnostics Inc. with a Hold rating due to upcoming catalysts and pending FDA submission for GraftAssureDx kidney transplant assay. IMDX's decentralized GraftAssureDx aims to disrupt the $1B+ transplant rejection testing market, offering cost-effective, localized testing versus centralized lab competitors. Key risks include clinical validation, regulatory approval uncertainty, software readiness, potential FDA delays, and a limited cash runway likely requiring further capital raises. Applying a Hold rating as IMDX advances toward FDA filing by end-2025 and eyes expansion into heart and lung transplant assays in 2026 and 2027. Read the full article on Seeking AlphaAnalysartikel • Nov 12
We Think Insight Molecular Diagnostics (NASDAQ:IMDX) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, Insight...Uppdatering av berättelse • Nov 12
IMDX: Increased Discount Rate Will Raise Uncertainty for Share Performance
Analysts have raised their price target for Insight Molecular Diagnostics from $5.42 to $6.13, citing improved revenue growth forecasts and higher profit margins as key factors contributing to the increased valuation. What's in the News Insight Molecular Diagnostics published study results in the American Journal of Transplantation, demonstrating the value of its GraftAssure assay for monitoring kidney transplant patients with severe complications.
Ny berättelse • Apr 13
GraftAssure Assay Submissions Will Unlock Transplant Center Opportunities
Strategic partnerships and anticipated regulatory approvals are poised to significantly expand OncoCyte's market reach, boosting revenue and supporting scalability.Aktieägarnas avkastning
| IMDX | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | -11.5% | -2.4% | 0.7% |
| 1Y | 77.6% | 35.9% | 20.6% |
Avkastning vs industri: IMDX översteg US Biotechs branschen som gav 36.1 % under det senaste året.
Avkastning vs Marknaden: IMDX översteg US marknaden som gav 19.5 % under det senaste året.
Prisvolatilitet
| IMDX volatility | |
|---|---|
| IMDX Average Weekly Movement | 17.8% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: IMDX s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: IMDX s veckovolatilitet ( 18% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av US aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2009 | 57 | Josh Riggs | www.imdxinc.com |
Insight Molecular Diagnostics Inc. är verksamt som ett företag inom precisionsdiagnostik i USA och internationellt. Bolaget utvecklar och kommersialiserar laboratorieutvecklade tester, kitted tester endast för forskningsändamål och kitted kliniska tester. Bolaget utvecklar DetermaCNI, ett blodbaserat övervakningsverktyg som upptäcker progression tidigt efter en cykel av cancerbehandling; och DetermaIO, ett genuttryckstest som bedömer tumörens mikromiljö för att förutsäga respons på immunterapier.
Insight Molecular Diagnostics Inc. Sammanfattning av grunderna
| IMDX grundläggande statistik | |
|---|---|
| Börsvärde | US$156.61m |
| Vinst(TTM) | -US$47.84m |
| Intäkter(TTM) | US$1.95m |
84.2x
P/S-förhållande-3.4x
P/E-förhållandeÄr IMDX övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| IMDX resultaträkning (TTM) | |
|---|---|
| Intäkter | US$1.95m |
| Kostnad för intäkter | US$954.00k |
| Bruttovinst | US$995.00k |
| Övriga kostnader | US$48.84m |
| Intäkter | -US$47.84m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -1.48 |
| Bruttomarginal | 51.05% |
| Nettovinstmarginal | -2,454.64% |
| Skuld/egenkapitalförhållande | 0% |
Hur har IMDX utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/10 00:21 |
| Aktiekurs vid dagens slut | 2026/07/10 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Insight Molecular Diagnostics Inc. bevakas av 8 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Mark Massaro | BTIG |
| null null | KeyBanc Capital Markets Inc. |